IL163894A0 - New compounds - Google Patents
New compoundsInfo
- Publication number
- IL163894A0 IL163894A0 IL16389403A IL16389403A IL163894A0 IL 163894 A0 IL163894 A0 IL 163894A0 IL 16389403 A IL16389403 A IL 16389403A IL 16389403 A IL16389403 A IL 16389403A IL 163894 A0 IL163894 A0 IL 163894A0
- Authority
- IL
- Israel
- Prior art keywords
- new compounds
- compounds
- new
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Reproductive Health (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Communicable Diseases (AREA)
- Psychology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Virology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Oncology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- AIDS & HIV (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0200979A SE0200979D0 (sv) | 2002-03-28 | 2002-03-28 | New compounds |
PCT/SE2003/000508 WO2003082853A1 (en) | 2002-03-28 | 2003-03-28 | New compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
IL163894A0 true IL163894A0 (en) | 2005-12-18 |
Family
ID=20287447
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL16389403A IL163894A0 (en) | 2002-03-28 | 2003-03-28 | New compounds |
IL163894A IL163894A (en) | 2002-03-28 | 2004-09-02 | 2-hydroxy-3-heteroarylindole derivatives, pharmaceutical compositions comprising them and their uses in the preparation of medicaments |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL163894A IL163894A (en) | 2002-03-28 | 2004-09-02 | 2-hydroxy-3-heteroarylindole derivatives, pharmaceutical compositions comprising them and their uses in the preparation of medicaments |
Country Status (31)
Country | Link |
---|---|
US (2) | US7399780B2 (de) |
EP (2) | EP1492785B9 (de) |
JP (2) | JP3989444B2 (de) |
KR (1) | KR101014525B1 (de) |
CN (2) | CN1923812A (de) |
AR (1) | AR038996A1 (de) |
AT (1) | ATE416171T1 (de) |
AU (1) | AU2003216026B2 (de) |
BR (1) | BR0308196A (de) |
CA (1) | CA2476343C (de) |
CY (1) | CY1108823T1 (de) |
DE (1) | DE60325032D1 (de) |
DK (1) | DK1492785T3 (de) |
ES (1) | ES2316784T3 (de) |
IL (2) | IL163894A0 (de) |
IS (1) | IS7471A (de) |
MX (1) | MXPA04009163A (de) |
MY (1) | MY144659A (de) |
NO (1) | NO329884B1 (de) |
NZ (1) | NZ534664A (de) |
PL (1) | PL211096B1 (de) |
PT (1) | PT1492785E (de) |
RU (1) | RU2338742C2 (de) |
SA (1) | SA03240054B1 (de) |
SE (1) | SE0200979D0 (de) |
SI (1) | SI1492785T1 (de) |
TW (1) | TWI330081B (de) |
UA (1) | UA79447C2 (de) |
UY (1) | UY27740A1 (de) |
WO (1) | WO2003082853A1 (de) |
ZA (1) | ZA200407665B (de) |
Families Citing this family (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE0302546D0 (sv) * | 2003-09-24 | 2003-09-24 | Astrazeneca Ab | New compounds |
US20040067985A1 (en) * | 2002-10-04 | 2004-04-08 | Fortuna Haviv | Method of inhibiting angiogenesis |
EP1778669A2 (de) | 2004-08-18 | 2007-05-02 | Takeda San Diego, Inc. | Kinase-inhibitoren |
EP1812439B2 (de) | 2004-10-15 | 2017-12-06 | Takeda Pharmaceutical Company Limited | Kinaseinhibitoren |
MX2007015627A (es) * | 2005-06-10 | 2008-02-21 | Pioneer Hi Bred Int | Metodo para uso de clasificacion ambiental en la seleccion de productos. |
EP2258358A3 (de) | 2005-08-26 | 2011-09-07 | Braincells, Inc. | Neurogenese mit Acetylcholinesterasehemmer |
JP2009506069A (ja) | 2005-08-26 | 2009-02-12 | ブレインセルス,インコーポレイティド | ムスカリン性受容体調節による神経発生 |
US8119655B2 (en) | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
WO2007047978A2 (en) | 2005-10-21 | 2007-04-26 | Braincells, Inc. | Modulation of neurogenesis by pde inhibition |
EP1942879A1 (de) | 2005-10-31 | 2008-07-16 | Braincells, Inc. | Gaba-rezeptor-vermittelte modulation von neurogenese |
WO2007089193A1 (en) * | 2006-02-02 | 2007-08-09 | Astrazeneca Ab | A process for preparing 2-hydroxy-3- [5- (morpholin-4-ylmethyl)pyridin-2-yl] lh-indole-5-carbonitrile as a free base or salts thereof |
US20090221576A1 (en) * | 2006-02-02 | 2009-09-03 | Astrazeneca Ab Global Intellectual Property | Pharmaceutical Use of 2-Hydroxy-3-[5-(Morpholin-4-Ylmethyl) Pyridin-2-YL]-1H-IN-Dole-5-Carbonitrile as a Free Base or Salts |
SA07280004B1 (ar) * | 2006-02-02 | 2011-10-29 | استرازينيكا ايه بي | ملح سترات من مركب 2- هيدروكسي –3- [5- (مورفولين –4- يل ميثيل) بيريدين –2- يل] 1h- إندول –5- كربونيتريل سترات |
EP1991539A4 (de) * | 2006-02-28 | 2010-08-25 | Astrazeneca Ab | Neue salze eines indolderivats und ihre verwendung in der medizin |
US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
WO2007120102A1 (en) * | 2006-04-19 | 2007-10-25 | Astrazeneca Ab | New substituted oxindole derivatives |
JP2009536669A (ja) | 2006-05-09 | 2009-10-15 | ブレインセルス,インコーポレイティド | アンジオテンシン調節による神経新生 |
US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
US20080086340A1 (en) * | 2006-10-04 | 2008-04-10 | Pioneer Hi-Bred International, Inc. | Crop quality insurance |
SG158147A1 (en) | 2006-10-09 | 2010-01-29 | Takeda Pharmaceutical | Kinase inhibitors |
MX2009004140A (es) | 2006-10-21 | 2009-07-10 | Abbott Gmbh & Co Kg | Compuestos heterociclicos y su uso como inhibidores de la glucogeno sintasa quinasa 3. |
WO2008083062A1 (en) | 2006-12-29 | 2008-07-10 | Pioneer Hi-Bred International, Inc. | Automated location-based information recall |
WO2008130312A1 (en) | 2007-04-18 | 2008-10-30 | Astrazeneca Ab | A new process for the manufacturing of the compound 2-hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]1h-indole-5-carbonitrile 701 |
WO2009017453A1 (en) * | 2007-07-30 | 2009-02-05 | Astrazeneca Ab | New therapeutic combination of an antipsychotic and a gsk3 inhibitor 958 |
WO2009017452A1 (en) * | 2007-07-30 | 2009-02-05 | Astrazeneca Ab | New crystalline forms of 2 -hydroxy- 3- [5- (morpholin- 4- ylmethyl) pyridin-2-yl] ih- indole- 5 -carbonitrile citrate |
WO2009017454A1 (en) * | 2007-07-30 | 2009-02-05 | Astrazeneca Ab | New therapeutic combination of a gsk3 inhibitor and an a7-nicotinic agonist 960 |
WO2009017455A1 (en) * | 2007-07-30 | 2009-02-05 | Astrazeneca Ab | A new combination of (a) an alpha-4-beta-2 -neuronal nicotinic agonist and (b) a gsk3 inhibitor |
EP3037419B1 (de) * | 2007-09-06 | 2019-09-04 | Boston Biomedical, Inc. | Zusammensetzungen von kinaseinhibitoren und ihre verwendung zur behandlung von krebs und anderen mit kinasen in zusammenhang stehenden krankheiten |
US20090291982A1 (en) * | 2008-05-22 | 2009-11-26 | Astrazeneca Ab | New Substituted Oxindole Derivative 352 |
US20100216805A1 (en) | 2009-02-25 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
TW201040191A (en) | 2009-03-27 | 2010-11-16 | Abbott Gmbh & Co Kg | Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors |
WO2010143803A2 (en) * | 2009-06-08 | 2010-12-16 | Industry Foundation Of Chonnam National University | New nicotinamide derivatives with anti-androgen effects, processes of preparing, and antiandrogens comprising the same |
JP2011178752A (ja) * | 2010-03-03 | 2011-09-15 | Nagoya Univ | 含窒素複素環化合物及びその製造方法 |
CA2810954A1 (en) | 2010-09-27 | 2012-04-05 | Abbott Gmbh & Co. Kg | Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors |
MX2013006467A (es) | 2010-12-09 | 2013-10-01 | Amgen Inc | Compuestos biciclicos como inhibidores pim. |
MX2013006694A (es) | 2010-12-21 | 2013-07-29 | Bayer Ip Gmbh | Procedimiento para producir oxindoles sustituidos con triazinilo. |
US9090592B2 (en) | 2010-12-30 | 2015-07-28 | AbbVie Deutschland GmbH & Co. KG | Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors |
AU2012230890A1 (en) | 2011-03-22 | 2013-09-26 | Amgen Inc. | Azole compounds as Pim inhibitors |
PL2970890T3 (pl) | 2013-03-14 | 2020-11-16 | The Brigham And Women's Hospital, Inc. | Kompozycje i sposoby ekspansji i hodowli nabłonkowych komórek macierzystych |
WO2016008966A1 (en) | 2014-07-17 | 2016-01-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for treating neuromuscular junction-related diseases |
AU2015311816B2 (en) | 2014-09-03 | 2019-04-04 | Massachusetts Institute Of Technology | Compositions, systems, and methods for generating inner ear hair cells for treatment of hearing loss |
WO2016207366A1 (en) | 2015-06-26 | 2016-12-29 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of viral infections |
GB201519573D0 (en) | 2015-11-05 | 2015-12-23 | King S College London | Combination |
US11021687B2 (en) | 2016-01-08 | 2021-06-01 | The Brigham And Women's Hospital, Inc. | Production of differentiated enteroendocrine cells and insulin producing cells |
US11260130B2 (en) | 2016-03-02 | 2022-03-01 | Frequency Therapeutics, Inc. | Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using a GSK3 inhibitor: IV |
US10201540B2 (en) | 2016-03-02 | 2019-02-12 | Frequency Therapeutics, Inc. | Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I |
US10213511B2 (en) | 2016-03-02 | 2019-02-26 | Frequency Therapeutics, Inc. | Thermoreversible compositions for administration of therapeutic agents |
RU2648820C2 (ru) * | 2016-04-14 | 2018-03-28 | Общество с ограниченной ответственностью "Научно-исследовательский центр "Парк активных молекул" | Средство, обладающее противоклоногенной активностью в отношении опухолевых клеток человека |
SG10201910821XA (en) | 2016-12-30 | 2020-01-30 | Frequency Therapeutics Inc | 1h-pyrrole-2,5-dione compounds and methods of using them to induce self-renewal of stem/progenitor supporting cells |
CN108440401A (zh) * | 2018-04-13 | 2018-08-24 | 华东理工大学 | 5-[(4-乙基哌嗪-1-基)甲基]吡啶-2-胺的制备方法 |
EP3837351A1 (de) | 2018-08-17 | 2021-06-23 | Frequency Therapeutics, Inc. | Zusammensetzungen und verfahren zur herstellung von haarzellen durch herunterregulierung von foxo |
WO2020037323A1 (en) | 2018-08-17 | 2020-02-20 | Frequency Therapeutics, Inc. | Compositions and methods for generating hair cells by upregulating jag-1 |
JP2022520671A (ja) | 2019-02-08 | 2022-03-31 | フリークエンシー・セラピューティクス・インコーポレイテッド | 耳障害を治療するためのバルプロ酸化合物及びwnt作動薬 |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3948910A (en) * | 1973-12-28 | 1976-04-06 | The Dow Chemical Company | Aminohalopyridine-N-oxides |
US4110466A (en) * | 1976-08-10 | 1978-08-29 | Sumitomo Chemical Company, Limited | Oxyindole compound |
NZ192948A (en) * | 1979-03-09 | 1982-02-23 | Ishihara Sangyo Kaisha | Preparation of beta-trifuloromethyl-pyridine derivatives directly from beta-picoline |
GB8401288D0 (en) * | 1984-01-18 | 1984-02-22 | Pfizer Ltd | Therapeutic agents |
US5710158A (en) | 1991-05-10 | 1998-01-20 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
FR2708605A1 (fr) * | 1993-07-30 | 1995-02-10 | Sanofi Sa | Dérivés du N-sulfonylindol-2-one, leur préparation, les compositions pharmaceutiques en contenant. |
FR2686878B1 (fr) * | 1992-01-30 | 1995-06-30 | Sanofi Elf | Derives du n-sulfonyl oxo-2 indole, leur preparation, les compositions pharmaceutiques en contenant. |
US5565580A (en) * | 1994-01-27 | 1996-10-15 | Neurosearch A/S | Glutamate Antagonists |
CZ288955B6 (cs) | 1994-02-23 | 2001-10-17 | Pfizer Inc. | Substituované chinazolinové deriváty, jejich pouľití a farmaceutické prostředky na jejich bázi |
TW574214B (en) | 1994-06-08 | 2004-02-01 | Pfizer | Corticotropin releasing factor antagonists |
GB9707800D0 (en) | 1996-05-06 | 1997-06-04 | Zeneca Ltd | Chemical compounds |
ATE368665T1 (de) | 1997-08-22 | 2007-08-15 | Astrazeneca Ab | Oxindolylchinazolinderivate als angiogenesehemmer |
CA2340701C (en) | 1998-08-20 | 2009-05-26 | Sumitomo Pharmaceuticals Co., Ltd. | Oxindole derivatives as growth hormone releasers |
JP4649046B2 (ja) | 1999-05-21 | 2011-03-09 | ブリストル−マイヤーズ スクイブ カンパニー | キナーゼのピロロトリアジン阻害剤 |
MXPA02003436A (es) | 1999-10-07 | 2002-08-20 | Amgen Inc | Inhibidores de triazina cinasa. |
US6455525B1 (en) * | 1999-11-04 | 2002-09-24 | Cephalon, Inc. | Heterocyclic substituted pyrazolones |
EP1136493A1 (de) | 2000-03-23 | 2001-09-26 | Sanofi-Synthelabo | 2-(Thienopyridinyl)pyrimidon-, 2-(Furopyridinyl)pyrimidon-2-(isoquinolinyl)pyrimidon-, 2-(Pyridoindolyl)pyrimidon- und 2-(Benzofuropyridinyl)pyrimidonderivate |
JP3984157B2 (ja) | 2000-07-27 | 2007-10-03 | エフ.ホフマン−ラ ロシュ アーゲー | グリコーゲンシンターゼキナーゼ−3ベータのインヒビターとしての3−インドリル−4−フェニル−1h−ピロール−2,5−ジオン誘導体 |
CA2425771A1 (en) | 2000-10-13 | 2002-04-18 | Christopher G. Boissard | Selective maxi-k- potassium channel openers functional under conditions of high intracellular calcium concentration, methods and uses thereof |
SE0104341D0 (sv) | 2001-12-20 | 2001-12-20 | Astrazeneca Ab | New use |
SE0104340D0 (sv) | 2001-12-20 | 2001-12-20 | Astrazeneca Ab | New compounds |
TW200301123A (en) | 2001-12-21 | 2003-07-01 | Astrazeneca Uk Ltd | New use |
EP1458711B1 (de) | 2001-12-21 | 2007-07-18 | AstraZeneca AB | Verwendung von oxindolderivaten zur behandlung von mit demenz in zusammenhang stehenden krankheiten, alzheimer-krankheit und mit glycogensynthasekinase-3 assoziierten leiden |
SE0302546D0 (sv) * | 2003-09-24 | 2003-09-24 | Astrazeneca Ab | New compounds |
KR20050008787A (ko) * | 2002-06-05 | 2005-01-21 | 얀센 파마슈티카 엔.브이. | 키나제 저해제로서의 비스인돌릴-말레이미드 유도체 |
-
2002
- 2002-03-28 SE SE0200979A patent/SE0200979D0/xx unknown
-
2003
- 2003-03-17 AR ARP030100931A patent/AR038996A1/es unknown
- 2003-03-19 TW TW092106042A patent/TWI330081B/zh not_active IP Right Cessation
- 2003-03-26 SA SA03240054A patent/SA03240054B1/ar unknown
- 2003-03-26 MY MYPI20031117A patent/MY144659A/en unknown
- 2003-03-28 JP JP2003580319A patent/JP3989444B2/ja not_active Expired - Fee Related
- 2003-03-28 BR BR0308196-6A patent/BR0308196A/pt not_active IP Right Cessation
- 2003-03-28 PT PT03745498T patent/PT1492785E/pt unknown
- 2003-03-28 CN CNA2006101537141A patent/CN1923812A/zh active Pending
- 2003-03-28 US US10/509,268 patent/US7399780B2/en not_active Expired - Lifetime
- 2003-03-28 AU AU2003216026A patent/AU2003216026B2/en not_active Ceased
- 2003-03-28 WO PCT/SE2003/000508 patent/WO2003082853A1/en active Application Filing
- 2003-03-28 NZ NZ534664A patent/NZ534664A/en not_active IP Right Cessation
- 2003-03-28 MX MXPA04009163A patent/MXPA04009163A/es active IP Right Grant
- 2003-03-28 EP EP03745498A patent/EP1492785B9/de not_active Expired - Lifetime
- 2003-03-28 CN CNB038073897A patent/CN100519550C/zh not_active Expired - Fee Related
- 2003-03-28 KR KR1020047015389A patent/KR101014525B1/ko not_active Expired - Fee Related
- 2003-03-28 IL IL16389403A patent/IL163894A0/xx unknown
- 2003-03-28 UA UA20040806742A patent/UA79447C2/uk unknown
- 2003-03-28 AT AT03745498T patent/ATE416171T1/de active
- 2003-03-28 DK DK03745498T patent/DK1492785T3/da active
- 2003-03-28 RU RU2004125146/04A patent/RU2338742C2/ru not_active IP Right Cessation
- 2003-03-28 CA CA2476343A patent/CA2476343C/en not_active Expired - Fee Related
- 2003-03-28 DE DE60325032T patent/DE60325032D1/de not_active Expired - Lifetime
- 2003-03-28 EP EP08157461A patent/EP1961748A3/de not_active Withdrawn
- 2003-03-28 UY UY27740A patent/UY27740A1/es not_active Application Discontinuation
- 2003-03-28 SI SI200331526T patent/SI1492785T1/sl unknown
- 2003-03-28 ES ES03745498T patent/ES2316784T3/es not_active Expired - Lifetime
- 2003-03-28 PL PL372966A patent/PL211096B1/pl not_active IP Right Cessation
-
2004
- 2004-09-02 IL IL163894A patent/IL163894A/en not_active IP Right Cessation
- 2004-09-22 ZA ZA200407665A patent/ZA200407665B/en unknown
- 2004-09-27 IS IS7471A patent/IS7471A/is unknown
- 2004-10-19 NO NO20044432A patent/NO329884B1/no not_active IP Right Cessation
-
2007
- 2007-06-13 JP JP2007155810A patent/JP2007224051A/ja active Pending
-
2008
- 2008-06-17 US US12/140,510 patent/US20090149460A1/en not_active Abandoned
-
2009
- 2009-02-19 CY CY20091100196T patent/CY1108823T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI341314B (en) | New compounds | |
IL177933A0 (en) | New compounds | |
IL166650A0 (en) | New compounds | |
AU2003264018A8 (en) | New compounds | |
IL163894A0 (en) | New compounds | |
EP1558585A4 (de) | Neurologisch aktive verbindungen | |
GB0209022D0 (en) | Compounds | |
GB0200283D0 (en) | Compounds | |
HU0203976D0 (en) | New compounds | |
AU2003216859A8 (en) | Amidoacetonitrile compounds | |
GB0210762D0 (en) | Compounds | |
GB0211418D0 (en) | Compounds | |
GB0207323D0 (en) | Compounds | |
GB0203778D0 (en) | Compounds | |
GB0212399D0 (en) | Compounds | |
AU2003275480A8 (en) | Compounds | |
GB0209244D0 (en) | Compounds | |
GB0203811D0 (en) | Compounds | |
GB0206981D0 (en) | Compounds | |
GB0204065D0 (en) | Compounds | |
GB0212401D0 (en) | Compounds | |
GB0203900D0 (en) | Compounds | |
GB0203812D0 (en) | Compounds | |
GB0204721D0 (en) | Compounds | |
GB0203191D0 (en) | Compounds |